Could less radiation be better for prostate cancer? new trial investigates

NCT ID NCT07674225

Ongoing Disease control Sponsor: Sunnybrook Health Sciences Centre Source: ClinicalTrials.gov ↗

First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time

Summary

This trial tests whether giving a lower dose of radiation in just two sessions can reduce urinary side effects for men with intermediate-risk prostate cancer. All participants receive radiation on an MR-Linac, a machine that combines MRI imaging with radiotherapy for precise targeting. Half receive a uniform dose, while the other half get a reduced dose. The study tracks side effects, quality of life, and PSA levels to see if the lower dose is safer without compromising cancer control.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: radiation therapy (SBRT on MR-Linac)
What this could lead to: If successful, this could lead to a standard treatment that reduces urinary side effects for men with intermediate-risk prostate cancer.
What could go wrong: This is a small early-phase trial with only 24 participants, so results may not apply broadly. Lowering the dose might also reduce cancer control.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INTERMEDIATE RISK PROSTATE CANCER (DIAGNOSIS) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

disease prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

INTERMEDIATE RISK PROSTATE CANCER (DIAGNOSIS) PROSTATE CANCER

Contacts and locations

Locations

Sunnybrook Health Sciences Centre

Toronto, Ontario, M4Y 2J3, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.